Sota Kuno
9channn.bsky.social
Sota Kuno
@9channn.bsky.social
Postdoc in Michael Pacold Lab @ NYU Langone Health
Reposted by Sota Kuno
Out now:

rdcu.be/evxCv

We've used CoQ10 headgroup intermediates to treat mouse models of a mitochondrial disease and improve the neurological symptoms of a patient with this disease.

Grateful for funding from @damonrunyon.org , Pershing Square Foundation, @americancancersoc.bsky.social, NIH!
Coenzyme Q headgroup intermediates can ameliorate a mitochondrial encephalopathy - Nature
Decreased brain coenzyme Q10 levels cause encephalopathy and are associated with neurodegeneration; supplementation with 4-HMA or 4-HB restores coenzyme Q10 synthesis in mice and humans with HPDL vari...
www.nature.com
July 9, 2025 at 5:32 PM
Reposted by Sota Kuno
I’m excited to share our new review published in @npp-journal.bsky.social 📣

“Impact of Early Social Isolation on Social Circuits and Behavior: Relevance to Schizophrenia”

www.nature.com/articles/s41...
Impact of early social isolation on social circuits and behavior: relevance to schizophrenia - Neuropsychopharmacology
Neuropsychopharmacology - Impact of early social isolation on social circuits and behavior: relevance to schizophrenia
www.nature.com
July 13, 2025 at 7:58 PM
Reposted by Sota Kuno
Excited to share our latest Nature publication, headed by the Pacold lab. Our experimental compound shows great promise as a novel, mechanistic treatment for a pediatric disorder that can prove fatal. It also highlights the therapeutic relevance of the cerebellum. #neuroskyence tinyurl.com/yh9736m9
Coenzyme Q headgroup intermediates can ameliorate a mitochondrial encephalopathy - Nature
Decreased brain coenzyme Q10 levels cause encephalopathy and are associated with neurodegeneration; supplementation with 4-HMA or 4-HB restores coenzyme Q10 synthesis in mice and humans with HPDL vari...
www.nature.com
July 11, 2025 at 8:02 PM